New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 4, 2012
11:34 EDTALXNAlexion:Data show long-term benefits of chronic Soliris therapy in aHUS patients
Alexion Pharmaceuticals announced the presentation of two-year data that highlight the long-term benefits of chronic Soliris, eculizumab, therapy in patients with atypical hemolytic uremic syndrome, aHUS, an ultra-rare genetic disease characterized by thrombotic microangiopathy, TMA, the formation of blood clots in small blood vessels throughout the body. In two pivotal phase 2 studies, which initially enrolled 37 patients, 32 patients entered a long-term extension phase. The data demonstrated that ongoing Soliris treatment for two years was associated with sustained inhibition of complement-mediated TMA, as indicated by a maintained increase in platelet count, and sustained improvement in renal function and TMA event-free status.1,2 The data were presented today at Kidney Week 2012, the annual meeting of the American Society of Nephrology, ASN, in San Diego. Additionally, data presented in a poster session at ASN support early initiation of Soliris therapy regardless of the presence or absence of genetic mutations in patients with aHUS.
News For ALXN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2015
07:53 EDTALXNFDA PDUFA Date for Alexion's Asfotase Alfa is September 2, 2015
Subscribe for More Information
September 1, 2015
17:57 EDTALXNAlexion CEO sees slow sales uptake for Kanuma, Strensiq, Reuters says
In a Reuters interview following EU approval of the company's Strensiq and Kanuma treatments, Alexion CEO David Hallal said he expects a slow sales uptake for the two drugs, adding that boosting disease awareness and finding patients is a challenge. "It takes time to reach the patients and the physicians. When we launch, it's usually one patient at a time," said Hallal. The CEO also remarked that the company is targeting similar pricing between the U.S. and elsewhere. Reference Link
05:39 EDTALXNAlexion granted marketing authorization for Kanuma in EU
Subscribe for More Information
05:38 EDTALXNAlexion granted marketing authorization for Strensiq in EU
Subscribe for More Information
August 31, 2015
19:28 EDTALXNAlexion initiated with a Strong Buy at Raymond James
Target $225.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use